VD's Model Portfolio & Discussion Thread Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Vector1 who wrote (7668)	3/6/2000 1:52:00 AM
From: Torben Noerup Nielsen	Read Replies (1) of 9719

V1, >Type 336 serotype, for which Nabi has patent protection >and will be folding into a trivalent vaccine in the >future. This is why I rate NABI higher than others developing vaccines for S. aureus. It's a serious problem in nosocomic situations as drug resistance is growing rapidly. The trivalent vaccine will have significantly improved coverage and no one else can match it at the moment. >Nabi© Altastaph? is a specific human antibody-based >product that contains high levels of antibodies against S. >aureus. Take a close look at the way they're shaping their revenue flow. Out of general antibody cocktails and into specific ones. This could prove invaluable in fighting drug resistant S. aureus infections in patients that were not vaccinated. The initial vaccine market would probably be the entire health care staff along with people at particularly high risk. This includes hospital patients, people in nursing homes and so forth. And I wouldn't ignore NicVAX. Yes, it's a joker in the deck and it's really hard to tell what it'll result in over time. But it could be a blockbuster all by itself. While the plasma derived products aren't that exciting, they pay the bills and you should note that they've been working hard on changing the revenue mix. Moreover, the work they do on the plasma products gives them what I consider a fantastic source of raw material to look at. So it makes money and it potentially feeds into the research side. Also, do not ignore the veterinary market. Bovine mastitis may not be all that exciting to think about, but given the cost to the industry of $200 per dairy cow, there's money there. Lots of it. And you do not need consent forms from cows. You also get to conduct safety tests after efficacy tests... Disclaimer: I own around 10K shares of NABI and I'm considering adding more. My two cents worth. I like this one and I think it belongs in any aggressive portfolio. I bought small chunks at the beginning of the year, but now that it's over $10, I'm willing to buy larger chunks. Thanks, Torben

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next